semaglutide

Documents about semaglutide

• Subcutaneous Semaglutide in Systemic Scleroderma#238222ClinicalTrials.gov
• Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly#121229ClinicalTrials.gov
• Semaglutide 2.4 mg in Patients With Poor Weight-loss#807282ClinicalTrials.gov
• Coronary Flow Reserve Changes After Semaglutide Treatment#830882ClinicalTrials.gov
• Semaglutide Use in Elderly Obese Patients#807823ClinicalTrials.gov
• A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)#180290ClinicalTrials.gov
• Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome#373774ClinicalTrials.gov
• SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes#992438ClinicalTrials.gov
• The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes#195497ClinicalTrials.gov
• Semaglutide and Intestinal Iron Absorption#886387ClinicalTrials.gov
• Semaglutide 2.4mg for Low Responders After Bariatric Surgery#907736ClinicalTrials.gov
• Comparative effectiveness of semaglutide and tirzepatide in patients with type 2 diabetes mellitus#990850African Journals Online
• Semaglutide vs Dulaglutide on Epicardial Adipose Tissue#158140ClinicalTrials.gov
• Semaglutide and Preoperative Residual Gastric Volumes#900597ClinicalTrials.gov
• Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology#154875ClinicalTrials.gov
• Effect of a Low-carbohydrate Diet on Weight Loss in People Using the Injectable GLP-1 Agonist Semaglutide for Weight Loss#874985ClinicalTrials.gov
• Plain language summary: the evoke(+) studies of semaglutide for early Alzheimer's disease#642368Europe PMC
• Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction#838595ClinicalTrials.gov
• Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination#980855ClinicalTrials.gov
• Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)#18565ClinicalTrials.gov
• Semaglutide alters the human embryo-endometrium interface#471379bioRxiv / medRxiv
• Sleeve Gastrectomy vs. GLP-1 Agonists (Semaglutide): A Cost-Effectiveness Perspective on Long-Term Obesity Management#169096DigitalCommons@WayneState
• Effect of Subcutaneous Semaglutide on Diabetic Retinopathy among Adults with Type 2 Diabetes in Saudi Arabia. A Systematic Review#438779HAL (France)
• Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves#827237ClinicalTrials.gov
• Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?#899455ClinicalTrials.gov
• Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes#651215ClinicalTrials.gov
• Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke#918163ClinicalTrials.gov
• Plain language summary: the evoke(+) studies of semaglutide for early Alzheimer’s disease#205386Figshare
• DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy#217181ClinicalTrials.gov
• Real-world Health Outcomes in Canadian Patients Using Semaglutide#407860ClinicalTrials.gov
• Impact of Semaglutide on CD34+ EPC and Fat Derived MSC#444858ClinicalTrials.gov
• Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy#918571ClinicalTrials.gov
• Optimizing Albuminuria Treatment in CKD With Finerenone and Semaglutide#829843ClinicalTrials.gov
• Mechanisms of Semaglutide Therapy in Heart Failure Patients#969360ClinicalTrials.gov
• Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial.#235952NCBI PubMed Central
• Titration and discontinuation of semaglutide for weight management in commercially insured US adults.#258304NCBI PubMed Central
• Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes#332722ClinicalTrials.gov
• Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: A vigibase study#676773HAL (France)
• Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes.#840524ClinicalTrials.gov
• PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese Adults#885215ClinicalTrials.gov
• Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.#967871ClinicalTrials.gov
• Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance#895063ClinicalTrials.gov
• Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care#896241ClinicalTrials.gov
• Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes#141182ClinicalTrials.gov
• Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes#160250ClinicalTrials.gov
• A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity#267962ClinicalTrials.gov
• Formulation Engineering of Oral Semaglutide Tablets: Unleashing Gastric Intestinal Permeation with Sodium Caprate.#317899NCBI PubMed Central
• A Study Comparing the Dulaglutide Pen and the Semaglutide Pen#884775ClinicalTrials.gov
• Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects#968233ClinicalTrials.gov
• A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity#136247ClinicalTrials.gov